68Ga-NOTA-FAPI-04 PET/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [18F] FDG PET/CT

Wang, Guochang; Jin, Xiao; Zhu, Hua; Wang, Shuailiang; Ding, Jin; Zhang, Yan; Yang, Zhi; Wang, Xuejuan

doi:10.1007/s00259-020-04946-0

Cited by 24 publications

(24 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we also examined a diffuse large Bcell lymphoma which showed relatively low 68 Ga-FAPI uptake. FAP-negative tumor phenotypes have also previously been described in the literature, e.g., in differentiated thyroid carcinoma and renal cell cancer [16][17][18].…”

Section: Discussionmentioning

confidence: 69%

Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients

Giesel

Kratochwil

Schlittenhardt

et al. 2021

Eur J Nucl Med Mol Imaging

124

126

View full text Add to dashboard Cite

Purpose FAPI ligands (fibroblast activation protein inhibitor), a novel class of radiotracers for PET/CT imaging, demonstrated in previous studies rapid and high tumor uptake. The purpose of this study is the head-to-head intra-individual comparison of 68Ga-FAPI versus standard-of-care 18F-FDG in PET/CT in organ biodistribution and tumor uptake in patients with various cancers. Material and Methods This international retrospective multicenter analysis included PET/CT data from 71 patients from 6 centers who underwent both 68Ga-FAPI and 18F-FDG PET/CT within a median time interval of 10 days (range 1–89 days). Volumes of interest (VOIs) were manually drawn in normal organs and tumor lesions to quantify tracer uptake by SUVmax and SUVmean. Furthermore, tumor-to-background ratios (TBR) were generated (SUVmax tumor/ SUVmax organ). Results A total of 71 patients were studied of, which 28 were female and 43 male (median age 60). In 41 of 71 patients, the primary tumor was present. Forty-three of 71 patients exhibited 162 metastatic lesions. 68Ga-FAPI uptake in primary tumors and metastases was comparable to 18F-FDG in most cases. The SUVmax was significantly lower for 68Ga-FAPI than 18F-FDG in background tissues such as the brain, oral mucosa, myocardium, blood pool, liver, pancreas, and colon. Thus, 68Ga-FAPI TBRs were significantly higher than 18F-FDG TBRs in some sites, including liver and bone metastases. Conclusion Quantitative tumor uptake is comparable between 68Ga-FAPI and 18F-FDG, but lower background uptake in most normal organs results in equal or higher TBRs for 68Ga-FAPI. Thus, 68Ga-FAPI PET/CT may yield improved diagnostic information in various cancers and especially in tumor locations with high physiological 18F-FDG uptake.

show abstract

Section: Discussionmentioning

confidence: 69%

Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients

Giesel

Kratochwil

Schlittenhardt

et al. 2021

Eur J Nucl Med Mol Imaging

124

126

View full text Add to dashboard Cite

show abstract

“…In addition to the detection of the primary and several metastases, the authors report the presence of bilateral adrenal enhancement that they think might be caused by hormonotherapy-induced chronic inflammation [27]. In a case report by Wang et al, FAP-specific PET was used in a patient with gastric diffuse large B cell lymphoma and could successfully detect the primary even though lymphoma lesions, unlike other tumors, supposedly lack fibrosis [22]. No dedicated study on FAP-specific PET for target volume delineation in upper gastrointestinal tract tumors could be found.…”

Section: Upper Gastrointestinal Tractmentioning

confidence: 99%

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review

Windisch

Zwahlen

Koerber

et al. 2020

Cancers

View full text Add to dashboard Cite

Small molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. The purpose of this systematic review is therefore to summarize the evidence that has been gathered to date in patients and to discuss its possible implications for radiotherapy planning. The MEDLINE database was searched for the use of FAP-specific PET in cancer patients and the records were screened according to PRISMA guidelines. Nineteen studies were included. While dedicated analyses of FAP-specific PET for radiotherapy planning were available for glioblastoma, head and neck cancers, lung cancer, and tumors of the lower gastrointestinal tract, there is still very limited data for several epidemiologically significant cancers. In conclusion, FAP-specific PET represents a promising imaging modality for radiotherapy planning that warrants further research.

show abstract

“…5 Therefore, 68 Ga-FAPI PET/CT may be advantageous for the detection of cerebral, oropharyngeal, and peritoneal involvement of lymphoma lesions. [6][7][8]…”

Section: Figurementioning

confidence: 99%

“…Besides the liver, low background 68 Ga-FAPI activity was also observed in the brain, oropharynx, and peritoneal cavity 5. Therefore, 68 Ga-FAPI PET/CT may be advantageous for the detection of cerebral, oropharyngeal, and peritoneal involvement of lymphoma lesions [6][7][8].…”

mentioning

confidence: 99%

18F-FDG Versus 68Ga-FAPI PET/CT in Visualizing Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue

et al. 2021

View full text Add to dashboard Cite

The prevalence of primary hepatic mucosa-associated lymphoid tissue lymphomas is extremely low. In this case, we present 18 F-FDG and 68 Ga-FAPI PET/CT findings in a 76-year-old man with pathologically confirmed primary hepatic extranodal marginal zone lymphoma of mucosaassociated lymphoid tissue. 68 Ga-FAPI PET/CT showed a better tumor-tobackground ratio than 18 F-FDG PET/CT in the hepatic lesion because there is little 68 Ga-FAPI uptake in the liver parenchyma. This case indicates that 68 Ga-FAPI PET/CT may be an alternate method for evaluating hepatic involvement of lymphoma, especially for the non-FDG-avid lymphomas.

show abstract

68Ga-NOTA-FAPI-04 PET/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [18F] FDG PET/CT

Cited by 24 publications

References 3 publications

Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients

Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review

18F-FDG Versus 68Ga-FAPI PET/CT in Visualizing Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue

Contact Info

Product

Resources

About